Please ensure Javascript is enabled for purposes of website accessibility

Sanofi Rises 3% on Q1 Beats, CEO Coronavirus Vaccine Comments

By Eric Volkman – Apr 26, 2020 at 10:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharmaceutical giant says it's on track to hit its full-year earnings guidance.

Sanofi (SNY -2.46%) ended the week on an up note, buoyed by an encouraging quarterly earnings release and market-pleasing remarks its CEO made about potential SARS-CoV-2 coronavirus vaccine manufacturing.

For the pharmaceutical giant's Q1 of fiscal 2020, according to International Financial Reporting Standards, its net sales were 8.97 billion euros ($9.70 billion). That was nearly 7% higher on a year-over-year basis. Net income was 2.04 billion euros ($2.21 billion), an improvement of almost 16%. On a per-share basis, net profit was 1.63 euros ($1.76). 

Pharmacist discussing a medication with a patient.

Image source: Getty Images.

Those figures exceeded analyst estimates. On average, prognosticators following the company's stock were anticipating 8.83 billion euros ($9.55 billion) on the top line and a per-share net profit of 1.43 euros ($1.55).

During the quarter, Sanofi benefited from increased demand for products like over-the-counter painkillers and fever medications in the wake of the coronavirus outbreak. It said in a conference call discussing the quarter that it's on track to hit its full-year 2020 guidance of 5% growth in per-share earnings.

Sanofi is in the thick of the fight against the coronavirus; it currently has several active research projects for vaccines, one taking the form of a collaboration with peer pharmaceutical major GlaxoSmithKline. On Friday, Sanofi CEO Paul Hudson pointed out that his company is one of the very few that will be able to manufacture any SARS-CoV-2 vaccine at the scale required to satisfy what is certain to be immense global demand.

On Friday, Sanofi's stock rose higher than that of the broader equities market, closing the day just over 3% higher. 


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
$38.84 (-2.46%) $0.98
GSK Stock Quote
$29.98 (-1.41%) $0.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.